Navigation Links
Keryx Biopharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Date:10/19/2010

NEW YORK, Oct. 19 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at BioCentury's NewsMakers in the Biotech Industry Conference, being held at the Millennium Broadway Hotel and Conference Center in New York City.  Mr. Bentsur's presentation is scheduled to take place on Friday, October 22, 2010, at 2:00 p.m.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citra
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Lakeland Industries, Inc. (NASDAQ: ... protective clothing for industry, healthcare and to first responders ... its financial results for the fiscal 2013 fourth quarter ... 21, 2013 at stock market close and will conduct ... p.m. eastern. (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) ...
(Date:5/17/2013)... N.C. , May 17, 2013  Technology ... organizations communicate internally. Faced with a constantly evolving ... strategies and tactics for communicating with internal executives. ... of all the strategies, tactics and tools that ... In a new study, Best Practices, LLC ...
(Date:5/17/2013)... , May 17, 2013  Sony Biotechnology Inc. ... SP6800 Spectral Analyzer (SP6800).  Sony will be exhibiting and ... will be held at the San Diego ... California , from May 20 - 22.  ... analytical system, incorporating commercial audio-visual technologies into new and ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2
... Treated for Acute Coronary Syndromes,(ACS) Nearly Triples the ... March 26, 2007 /PRNewswire/ -- One-year findings,from the ... patients in the "Angiomax(R) (bivalirudin) alone" treatment,group had ... complicated standard therapy, confirming previous findings,which showed similar ...
... CSL Limited today,announced results from a study published in ... of a novel new,drug, CSL-111, to acutely raise HDL ... the coronary arteries of,patients with a recent episode of ... to describe unstable angina and myocardial,infarction (heart attack). It ...
Cached Medicine Technology:Acuity One-Year Findings Meet All Primary Endpoints in Favor of,Angiomax (Bivalirudin) Alone Treatment Group 2Acuity One-Year Findings Meet All Primary Endpoints in Favor of,Angiomax (Bivalirudin) Alone Treatment Group 3Acuity One-Year Findings Meet All Primary Endpoints in Favor of,Angiomax (Bivalirudin) Alone Treatment Group 4Acuity One-Year Findings Meet All Primary Endpoints in Favor of,Angiomax (Bivalirudin) Alone Treatment Group 5Acuity One-Year Findings Meet All Primary Endpoints in Favor of,Angiomax (Bivalirudin) Alone Treatment Group 6CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume,in Coronary Arteries 2CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume,in Coronary Arteries 3CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume,in Coronary Arteries 4
(Date:5/18/2013)... In “Cooking with Spirits for the Spirit: A ... Hall Svisdahl’s new cookbook, readers are transported into the world ... the pickiest eater drool. “I dedicate this book to the ... , Found within the 364 pages of “Cooking with Spirits ... from fast and simple to gourmet. Each recipe greets the ...
(Date:5/18/2013)... The American Society for Gastrointestinal Endoscopy (ASGE) will honor ... ninth annual ASGE Crystal Awards on Sunday, May 19, ... year,s event will begin at ... Held in conjunction with Digestive Disease Week (DDW), the ... and scientific pursuit. The event will recognize the 2013 ...
(Date:5/18/2013)... American Gastroenterological Association (AGA) Research Foundation is pleased ... honorees are outstanding young gastroenterologists working toward independent ... with this award, their research time will be ... future of our field. AGA is committed to ... for promising research developments and new therapies," said ...
(Date:5/18/2013)... May 18, 2013 Online watch retailer Time ... Rolex watch owners at a fraction of its usual ... timepieces in the world, buyers are urged to take advantage ... buying a Rolex watch from a brick-and-mortar store, buyers now ... watches priced at unbelievable rates. Although some buyers may ...
(Date:5/18/2013)... FRIDAY, May 17 (HealthDay News) -- As the American ... considered the "bible" of modern psychiatry this weekend, the ... unprecedented, the amount of commentary and debate and criticism," ... Association (APA). "It,s been an interesting phenomenon, but the ... it and then make your own determination of how ...
Breaking Medicine News(10 mins):Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 3Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 5Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 6Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 7Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4
... , , ATLANTA, July 28 ... today the opening of its first Asia office in Shanghai, China ... States and abroad. The new office will support the current and future business ... the world,s largest organizations. , , Currently, North Highland ...
... July 28 Cambrex Corporation (NYSE: CBM ) announced that second quarter 2009 financial results ... The Company will host a conference call to discuss the second quarter 2009 financial results. , ... Second Quarter 2009 Earnings Conference Call, When: ... Time, Dial-in: 1-888-634-4003 for U.S., ...
... available by fall or early winter , TUESDAY, July 28 ... against the new H1N1 swine flu set to begin shortly, ... a panel of experts Wednesday to recommend a priority list ... that a safe and effective vaccine will be available by ...
... , , ... 28 CVS Caremark (NYSE: CVS ) announced today ... President/Chief Operating Officer of MinuteClinic, the company,s retail-based health clinic subsidiary, ... In his new roles, Dr. Sussman will be responsible for ...
... ... ... hundreds of dollars on new digital hearing aids need look no further. ... utilizes a nationwide network of more than 1,200 professionals and offers discounts on a wide ...
... , MAITLAND, Fla. , July 28 ... for infants with plagiocephaly and other head shape abnormalities, opened a ... Center currently also has offices in the Baltimore and Dallas areas, ... also commonly referred to as a cranial helmets or headbands. , ...
Cached Medicine News:Health News:North Highland Opens First Asia Office in Shanghai 2Health News:CDC Panel to Recommend Who Should Get Swine Flu Shot 2Health News:CDC Panel to Recommend Who Should Get Swine Flu Shot 3Health News:CVS Caremark Names Andrew J. Sussman, M.D., as President/Chief Operating Officer of MinuteClinic 2Health News:CVS Caremark Names Andrew J. Sussman, M.D., as President/Chief Operating Officer of MinuteClinic 3Health News:Hearing Aid Savings Galore 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 3Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 4Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 5
GluStitch® is indicated for the closure of uncomplicated skin lacerations where there is little or no tissue loss....
... PT Medical allows your office ... to change how your practice functions. ... and paper you can easily add ... forms or any other documents that ...
Redwood Toxicology Laboratory is one of the world's premier forensic drug detection laboratories offering its customers scientifically accepted, legally defensible drug detection services....
For use in vitreo-retinal procedures with a non contact system, and compatible with the Oculus BIOM system, this lens delivers the highest image clarity available in a non contact surgical lens....
Medicine Products: